AKT1 and metabolic disease: This need is reflected in clinical trials showing that nonspecific Akt inhibition in cancer therapy, due to inadvertent off-targeting of closely related kinases or multiple Akt isozymes, can result in detrimental side effects including liver damage and metabolic disorders [39,40,41,42].